<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610388</url>
  </required_header>
  <id_info>
    <org_study_id>113376</org_study_id>
    <nct_id>NCT01610388</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first time in human (FTIH) study will be the first administration of GSK1322322 as an&#xD;
      intravenous formulation and will investigate safety, tolerability, and pharmacokinetics in&#xD;
      healthy subjects. One cohort of subjects will undergo bronchoalveolar lavage (BAL) for&#xD;
      determination of GSK1322322 concentrations in lung with simultaneous comparison to plasma&#xD;
      concentrations to evaluate drug penetration in the lung. The study will evaluate the absolute&#xD;
      bioavailability of an oral tablet formulation as compared to the IV formulation.In addition,&#xD;
      Amendment 01 will enable the investigation of an improved IV formulation (GSK1322322J&#xD;
      mesylate salt) in an additional repeat dosing cohort and the supra-therapeutic cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2011</start_date>
  <completion_date type="Actual">January 26, 2012</completion_date>
  <primary_completion_date type="Actual">January 26, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including the number of subjects with adverse events (AEs)</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including absolute values and changes over time of clinical safety laboratory assessments.</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including the change from baseline in vital signs (blood pressure (BP) and heart rate)</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 pharmacokinetic parameters (PK) after single oral dose, area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-∞)).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose aximum observed concentration (Cmax).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose time of occurrence of Cmax (tmax).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose mean residence time (MRTpo)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose apparent clearance after oral administration (CL/F)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose apparent volume of distribution after oral administration (Vz/F)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose terminal phase half-life (t 1/2).</measure>
    <time_frame>cohort B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose area under the concentration-time curve from zero (pre-dose) to some fixed nominal time (12 hours) (AUC(0-12)).</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose area under the concentration-time curve from zero (pre-dose) to some fixed nominal time (24 hours) AUC(0-24)</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose AUC(0-t)</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose AUC(0-∞).</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose Cmax</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose mean residence time intravenous (MRTiv)</measure>
    <time_frame>Cohort A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose t1/2</measure>
    <time_frame>Cohort A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability will be determined by comparing oral AUC(0-∞) to IV AUC(0-∞)</measure>
    <time_frame>Cohort B and C on Day -2 and Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAT of oral tablet will be determined (=MRTpo-MRTiv)</measure>
    <time_frame>Cohort B and C on Day -2 and Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including Area under the concentration-time curve over the dosing interval (AUC(0-τ))</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including Cmax</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including CL</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 concentrations in BAL obtained in epithelial lining fluid (ELF) and alveolar macrophages (AM) as compared to that in plasma</measure>
    <time_frame>Cohort C Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK1322322 urine PK parameters: amount excreted (Ae) of unchanged GSK1322322, fraction of the dose excreted in the urine (fe) and renal clearance (CLr) following single dose IV administration from Period 2 and Period 3.</measure>
    <time_frame>cohort B and C on Day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 6 GSK1322322 AUC(0-τ) compared to AUC(0-12) on Day 1 to evaluate the accumulation ratio following repeat IV administration of GSK1322322.</measure>
    <time_frame>Cohorts A, B, C Day 6 and Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 6 GSK1322322 AUC(0-τ) compared to AUC(0-∞) on Day 1 to evaluate time invariance following repeat IV administration of GSK1322322.</measure>
    <time_frame>Cohorts A, B, C Day 6 and Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322 PK parameters: AUC(0-∞) on Day 1 and AUC(0-τ) on Day 6 following IV administration at different doses for the assessment of dose proportionality.</measure>
    <time_frame>Cohorts A, B, C Day1 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome analysis of stool prior to and after exposure to GSK1322322</measure>
    <time_frame>Cohort A, B,C, D, E single sample predose and single sample post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including the number of subjects with adverse events (AEs)</measure>
    <time_frame>Cohort D and E up to 11 days, Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including absolute values and changes over time of clinical safety laboratory assessments</measure>
    <time_frame>Cohort D and E up to 11 days; Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including the change from baseline in vital signs (blood pressure (BP) and heart rate)</measure>
    <time_frame>Cohort D and E up to 11 days; Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Cohort D and E up to 11 days: Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 2000mg IV GSK1322322J/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 3000mg IV GSK1322322J/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg IV GSK1322322J/placebo followed by BID for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500mg IV GSK1322322/placebo</intervention_name>
    <description>500mg IV</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg oral GSK1322322/placebo</intervention_name>
    <description>1000mg oral</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg IV GSK1322322/placebo</intervention_name>
    <description>1000mg IV</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1500mg oral GSK1322322/placebo dose</intervention_name>
    <description>1500mg oral</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1500mg IV GSK1322322/placebo</intervention_name>
    <description>1500mg IV</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2000mg IV GSK1322322J/placebo</intervention_name>
    <description>2000mg IV</description>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3000mg IV GSK1322322J/placebo</intervention_name>
    <description>3000mg IV</description>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg IV GSK1322322J/placebo</intervention_name>
    <description>1000mg IV</description>
    <arm_group_label>Cohort F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including [medical history, physical examination, laboratory tests and&#xD;
             ECGs. A subject with a clinical abnormality or laboratory parameters outside the&#xD;
             reference range for the population being studied may be included at the discretion of&#xD;
             the Investigator only if the finding is unlikely to introduce additional risk factors&#xD;
             and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods listed in the protocol. This criterion must be followed from&#xD;
             the time of the first dose of study medication until the final follow up visit.&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kilograms and body mass index (BMI) between&#xD;
             18.5-29.9 (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcB less than 450 millisecond (msec); or QTcB less than 480 msec in subjects with&#xD;
             Bundle Branch Block on Screening ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Contraindications to bronchoalveolar lavage including hypercapnia greater than 50 mm&#xD;
             Hg, refractory hypoxemia, reactive airway disease or asthma, unstable angina or acute&#xD;
             myocardial infarction in the last 6 months, heart failure, and severe hemostatic&#xD;
             alterations (Cohort C only).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, and within 5 days following discontinuation of GSK1322322&#xD;
             (for sensitive and narrow therapeutic index CYP3A4 substrates), unless in the opinion&#xD;
             of the Investigator and GSK Medical Monitor the medication will not interfere with the&#xD;
             study procedures or compromise subject safety.&#xD;
&#xD;
          -  Use of antacids, H2 blockers, proton pump inhibitors, vitamins, and iron supplements&#xD;
             within 7 days prior to the first dose of study medication and for the duration of the&#xD;
             trial, including follow-up.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  History of sensitivity to medications used in study, ie Atropine, Midazolam, Fentanyl,&#xD;
             Lidocaine, Codeine (Cohort C only) that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliters within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive [serum or urine] test at screening or prior&#xD;
             to dosing.&#xD;
&#xD;
        Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices] from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
&#xD;
          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility&#xD;
             determination): Heart rate: males less than 45 and greater than 100 beats per minute&#xD;
             (bpm) and females less than 50 and greater than 100bpm. PR interval less than 120 and&#xD;
             greater than 220msec, QRS duration less than 70 and greater than 120 msec, and QTcB&#xD;
             greater than 450msec. Evidence of previous myocardial infarction (does not include ST&#xD;
             segment changes associated with repolarization). Any conduction abnormality (including&#xD;
             but not specific to left or right complete bundle branch block, AV block [2nd degree&#xD;
             or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses&gt; 3 seconds,&#xD;
             non-sustained or sustained ventricular tachycardia (greater than or equal to 3&#xD;
             consecutive ventricular ectopic beats) or any significant arrhythmia which, in the&#xD;
             opinion of the principal investigator and GSK medical monitor, will interfere with the&#xD;
             safety of the individual subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <keyword>double-blind</keyword>
  <keyword>FTIH</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>absolute bioavailability</keyword>
  <keyword>GSK1322322</keyword>
  <keyword>BAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

